Rafael Holdings, Inc. reported its financial results for the second quarter of fiscal 2026, revealing a total revenue of $211,000 for the three months ended January 31, 2026, compared to $77,000 for the same period in the previous year. The increase in revenue was primarily driven by product sales, which amounted to $125,000, marking a significant rise from zero in the prior year. However, the company recorded a consolidated net loss of $6.3 million for the quarter, an increase from a loss of $5.3 million in the same quarter of the previous year. For the six months ended January 31, 2026, total revenue reached $451,000, up from $205,000 in the prior year, while the net loss widened to $16.1 million from $14.5 million.
The financial performance reflects a strategic shift following the merger with Cyclo Therapeutics, which was completed on March 25, 2025. This merger has allowed Rafael to consolidate Cyclo's operations, contributing to the increase in product revenue. The company also reported a significant rise in research and development expenses, which totaled $12 million for the six months ended January 31, 2026, compared to $2.3 million in the prior year, largely due to Cyclo's ongoing clinical trials for its lead candidate, Trappsol® Cyclo™.
Operationally, Rafael Holdings has seen changes in its business structure, including a focus on its Healthcare segment, which now includes a 100% interest in Cyclo and a 95% interest in LipoMedix Pharmaceuticals. The company is also evaluating its other holdings to concentrate resources on core assets. As of January 31, 2026, Rafael Holdings had cash and cash equivalents of approximately $37.8 million, a decrease from $52.8 million at the end of the previous fiscal year, indicating a cash burn rate that the company is monitoring closely.
Looking ahead, Rafael Holdings expects to continue its focus on advancing Trappsol® Cyclo™ through clinical trials and regulatory approval, while also exploring strategic investments in therapeutics. The company anticipates that its current cash reserves will be sufficient to meet obligations for at least the next 12 months. However, the ongoing development and commercialization efforts will require careful management of resources and operational efficiencies to mitigate losses and enhance revenue generation.
About Rafael Holdings, Inc.
Rafael Holdings is a diversified investment company focused on advancing pharmaceutical and medical device innovations. It holds interests in clinical-stage biotech firms developing therapies for rare and neurodegenerative diseases, cancer, and medical devices. The company invests in therapeutics, supports pipeline development, and seeks strategic acquisitions, emphasizing high unmet medical needs. It also manages real estate assets and explores opportunities outside traditional biopharma markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.